A phase 1 trial reported all 38 evaluable participants with relapsed or refractory multiple myeloma responded to the investigational BCMA-targeted CAR-T therapy anito-cel, with a favorable safety profile. The results highlight durable long-term benefit signals across a relapsed population. The dataset adds to the growing evidence that BCMA CAR-T can achieve deep response rates, but it also raises the bar for next-line comparisons against existing CAR-T and bispecific antibody regimens. For developers, the trial’s emphasis on consistent responses supports continued focus on manufacturing reliability, immune persistence, and toxicity management as differentiation points in commercial CAR-T.